Continuous vs. Intermittent Infusion Vancomycin
Launched by AARON COOK · Apr 6, 2023
Trial Information
Current as of August 23, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying two different ways to give a medication called vancomycin, which is often used to treat infections in hospitalized patients. The researchers want to find out if giving vancomycin continuously (without breaks) is better or worse for kidney health compared to giving it intermittently (with breaks). The study is taking place at the University of Kentucky and is looking for adult patients aged 18 and older who are currently hospitalized and have been prescribed vancomycin.
To participate, individuals must be in good enough health to give consent and should not have certain kidney problems or other specific conditions. If eligible, participants will be randomly assigned to one of the two treatment groups and will have their kidney function closely monitored throughout the trial. This research is important because it could help doctors understand the best way to use vancomycin, potentially leading to better care for patients receiving this medication.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • ≥ 18 years of age
- • Hospitalized at University of Kentucky on a medical service (internal medicine or medical intensive care)
- • Prescribed ≥ 2 doses of vancomycin per treating physician
- • Be able to provide written, informed consent, or have a legally authorized representative (LAR) responsible for their care able to provide written, informed consent.
- Exclusion Criteria:
- • Chronic kidney disease (documented or prior to admission estimated GFR (eGFR) \<60 ml/min/1.73m2 using non-race-based creatinine GFR equation)
- • End stage kidney disease
- • Stage 1 or higher AKI per Kidney Disease: Improving Global Outcomes (KDIGO) classification (serum creatinine increase ≥ 0.3 mg/dl or 1.5-1.9 times baseline; urine output \< 0.5 ml/kg/hr for 6-12 hours)
- • Greater than 2 doses of vancomycin within the last 72 hours
- • Allergy to iohexol
- • Uroepithelial tumors
- • Pregnancy
- • Prisoner
About Aaron Cook
Aaron Cook is a dedicated clinical trial sponsor committed to advancing medical research through innovative and ethical trial designs. With a focus on developing safe and effective therapeutic solutions, the organization collaborates with a network of leading researchers and healthcare professionals to facilitate groundbreaking studies across various therapeutic areas. By prioritizing patient safety and regulatory compliance, Aaron Cook strives to contribute meaningful advancements to the healthcare landscape, ultimately enhancing patient outcomes and improving quality of life.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Lexington, Kentucky, United States
Lexington, Kentucky, United States
Patients applied
Trial Officials
Aaron M Cook, PharmD
Principal Investigator
University of Kentucky
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported